An Off-the-Shelf Drug to Rival CAR T Cells:'Very Exciting'An Off-the-Shelf Drug to Rival CAR T Cells:'Very Exciting '
A novel bispecific antibody, mosunetuzumab, has shown complete remissions in patients with poor prognosis non-Hodgkin's lymphoma, even those previously treated with CAR T cells.Medscape Medical News
CONCLUSIONS: Although pSS is associated with a higher risk of developing NHL, the risk of NHL appears to have decreased compared with that in previous studies. Our study suggests that the risk of NHL or thyroid cancer with SS is not higher than that reported in previous studies. PMID: 31969226 [PubMed - as supplied by publisher]
Authors: Vučićević Boras V, Vidović Juras D, Aurer I, Bašić-Kinda S, Mikulić M Abstract A 40-year-old female patient was admitted to the Department of Oral Medicine due to oral ulcerations. Oral ulcerations were present on vestibular mucosa above teeth 21, 22, 25 and 26 and were 1 cm in diameter, and also around teeth 45 and 46. The patient had prolonged neutropenia due to therapy-related myelodysplastic syndrome that progressed to therapy-related acute myeloid leukemia. Initially, the patient was successfully treated with polychemotherapy for non-Hodgkin lymphoma. Unfortunately, many toxic complicatio...
Historically, there have been limited curative treatment options for patients (pts) who relapse or have refractory Large B Cell Lymphoma (LBCL). Recently, autologous anti-CD19 chimeric antigen receptor T-Cell (CAR T) therapies were approved for the treatment of pts with relapsed or refractory LBCL after ≥ 2 prior systemic therapies.
We report on patients (pts) with R/R large B cell NHL treated with liso-cel in the outpatient setting in TRANSCEND NHL 001 (NCT02631044) and two phase 2 studies ( ≥3rd-line therapy: OUTREACH, NCT03744676; 2nd-line TNE: PILOT, NCT03483103).
Disease relapse is the most common cause of therapy failure in NHL patients undergoing RIC alloHCT. Whether increasing TBI dose from 2Gy to 4Gy in RIC-platform can provide improved disease control without increasing non-relapse mortality (NRM) is not known. Using the CIBMTR database we evaluated the outcomes of NHL patients receiving RIC alloHCT with either Flu/2Gy TBI vs. Flu/4Gy TBI.
Chimeric antigen receptor T cell (CAR-T cell) therapy has become a promising treatment for children with acute lymphoblastic leukaemia (ALL) and Non-Hodgkin lymphoma (NHL). Cytokine release syndrome (CRS) and Immune effector cell associated neurotoxicity syndrome (ICANS) are well-documented serious side-effects of CAR-T cell therapy, and early recognition, intervention and aggressive supportive therapy is paramount.Tociluzimab is the mainstay of treatment for moderate to severe CRS, with early administration essential.
Mainstay treatment options for patients with relapsed or refractory Hodgkin's lymphoma and Non-Hodgkin's lymphoma (NHL) include high dose chemotherapy and autologous stem cell transplantation (aSCT). Several chemotherapy regimens have been explored with various drug combinations. To date, no objective data is available to indicate that one particular regimen is better than another in regards to superiority. When selecting one regimen compared to another, the choice will depend on each institution's individual practices, guidelines, and toxicities associated with each regimen.
CAR T cell therapy has emerged as a breakthrough treatment for relapsed/refractory aggressive B cell non-Hodgkin lymphoma (B-NHL) providing impressive clinical response. CAR T cells, however, also have unique adverse events including cytokine release syndromes (CRS), neurological toxicity (ICANS), and B cell aplasia. To date, there are limited data on infectious complication after CAR T cell therapy. Herein, we report the incidence, patterns, risk factors and outcomes of infections in B-NHL patients treated with CD19 CAR T cells.
The objective of this study was to identify rates of infectious complications and febrile neutropenia at our institution. This retrospective single center study included 38 patients with relapsed, refractory non-Hodgkin lymphoma (NHL), who received CD19 directed CAR T-cell therapy axicabtagene ciloleucel, as standard of care for the treatment relapsed NHL between January, 2018 and October, 2019.
The objective of this study was to characterize the incidence of cytopenias and the utilization of growth factor and transfusion support following CAR T-cell therapy. This retrospective, single center study included 38 patients with relapsed, refractory non-Hodgkin lymphoma (NHL), who received CD19 directed CAR T-cell therapy, axicabtagene ciloleucel, as standard of care for the treatment relapsed NHL between January, 2018 and October, 2019.